Competitor ResultsHookipa shares have generally moved lower following the ASCO abstract release, likely on competitor results.
Stock Price RiskHOOK faces a delisting risk if the stock price does not stay above $1.00 for a required number of consecutive business days, making upcoming trial updates critical.
Trial ResultsThe recent update showed that HB-200 + pembro had a 20% ORR in CPS 1-19, which is at parity to the 19% ORR for pembro monotherapy, suggesting no broadening of responses with HB-200 in this subgroup.